The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations
- 205 Downloads
The process of selecting patients on the basis of epidermal growth factor receptor (EGFR) mutations would likely result in a patient population with greater sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, EGFR mutation status is not routinely examined in patients with squamous cell lung cancer (Sq) because of the low incidence of EGFR mutations and the poor clinical response to EGFR-TKIs.
We retrospectively reviewed the clinical features of patients at our hospital with Sq who carried EGFR-TKI-sensitive EGFR mutations and assessed their responses to EGFR-TKIs.
EGFR mutation status was tested in 23 of 441 patients with Sq (5.2%) admitted to our hospital during the study period. An EGFR mutation (exon 19 deletion 3, L858R 2) was identified in five of the 23 patients (21.7%), all of whom were female never-smokers. Of these five patients, four (4/9; 44.4%) were in the normal lung group, one (1/12; 8.3%) was in the emphysematous lung group, and none (0/2; 0%) in the fibrotic lung group. Two of these five patients with the EGFR mutation received gefitinib and two received afatinib. Although the two patients who were treated with gefitinib did not respond well to treatment (stable disease, 1 patient; progressive disease, 1 patient), the two patients who were treated with afatinib showed a good response (partial response, 2 patients).
The administration of afatinib to Sq patients after selecting patients using the EGFR mutation test based on their underlying pulmonary disease and smoking status would likely result in a population with a greater sensitivity to afatinib.
KeywordsSquamous cell lung cancer EGFR-TKI-sensitive EGFR mutation Afatinib
Compliance with ethical standards
The study protocol was reviewed and approved by the Ethics Committee of NTT Medical Center Tokyo.
Conflict of interest
The authors declare no conflicts of interest in association with the present study.
- 1.Center for Cancer Control and Information Services (2014) Cancer statistics in Japan 2014. Center for Cancer Control and Information Services, National Cancer Center Japan, Tokyo. https://ganjoho.jp/en/professional/statistics/brochure/2014_en.html
- 16.Liu Y, Zhang Y, Zhang L et al (2017) Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports. Oncotarget 8(30):49680–49688Google Scholar
- 18.Usui K, Ushijima T, Tanaka Y et al (2011) The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases. Pulm Med 290132:2011Google Scholar
- 22.Felip E, Soria JC, Cobo M et al (2017) Second-line afatinib versus erlotinib for patients with squamous cell carcinoma of the lung (Lux-Lung 8): analysis of tumor and serum biomarkers. J Thorac Oncol 12(1) [Suppl]:S1186–S118Google Scholar
- 23.Goss G, Felip E, Cobo M et al (2017) Impact of EGFR mutations on clinical outcomes in afatinib- or erlotinib- treated patients with SCC of the lung. J Thorac Oncol 12(11) [Suppl 2]:S2217–S2218Google Scholar